|

Rituximab and Hyaluronidase Human Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • University of Washington1
  • National Cancer Institute (NCI)1
  • Academic and Community Cancer Research United1

Indications

  • Cancer3
  • Follicular Lymphoma With Unusual Cytological Features1
  • Classic Follicular Lymphoma1
  • Grade 3b Follicular Lymphoma1
  • High-grade B-cell Lymphoma1

Birmingham, Alabama1 trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

University of Alabama at Birmingham Cancer Center

Phase 3

New Orleans, Louisiana1 trial

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Ochsner NCI Community Oncology Research Program

Phase 2

Seattle, Washington1 trial

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.